Exosome Diagnostics enters agreement with Merck KGa

Cambridge (US) based btov portfolio company, Exosome Diagnostics, has announced that it will be partnering with Darmstadt (DE) headquartered Merck, a leading multinational science and technology company, to help further the company’s drug development efforts in oncology and other therapeutic areas. This is the first public agreement which encompasses Exosome’s newly unveiled exosomal protein capture and quantitative analysis instrument, Shahky. For the full press release, please click here.